Novo Nordisk Faces Price Competition as Indian Generics Enter Weight-Loss Drug Market
As Indian generic drugmakers introduce lower-cost alternatives to Novo Nordisk's GLP-1 medications, the market dynamics are shifting, impacting competitors like Eli Lilly.
Summary
The introduction of affordable weight-loss drugs by Indian generic manufacturers is intensifying competition in the GLP-1 market, particularly against Novo Nordisk's established brands, Ozempic and Wegovy.
Eli Lilly has reportedly seen a decline in its market share in India as these cheaper semaglutide generics gain traction among consumers.
In response to the price pressure, Novo Nordisk has implemented significant price cuts to maintain its position and defend its products against the influx of generics.
Key Facts
| Fact | Value |
|---|---|
| Market Impact | Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge. |
| Novo Nordisk Strategy | Novo holds steady after deep price cuts to defend Ozempic, Wegovy. |
Updates
Update at 06:38 UTC on 2026-04-10
CNBC reported Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic, Wegovy.
Sources: CNBC